The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.10
Bid: 12.90
Ask: 13.30
Change: -0.10 (-0.76%)
Spread: 0.40 (3.101%)
Open: 13.20
High: 13.20
Low: 13.05
Prev. Close: 13.20
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: CentralNic and Pebble tip 2021 earnings rise

Mon, 17th Jan 2022 17:04

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

CentralNic Group PLC - London-based domain name registry and registrar services firm - Says organic growth "accelerated" in fourth quarter, which CentralNic attributes to "significant investment programme". For 2021, organic growth was 37%. Expects annual revenue of USD450 million and adjusted earnings before interest, tax, depreciation and amortisation of around USD45 million. This would be ahead of revenue consensus of USD383 million and adjusted Ebitda consensus of USD42.9 million. Would represent 70% revenue growth and 47% climb in adjusted Ebitda from 2020.

----------

Pebble Group PLC - Manchester-based technology and services for promotional products industry - Says revenue for 2021 to be around GBP115 million, up from GBP82.4 million in 2020 and beating 2019's GBP107.2 million, which was before onset of pandemic. It expects an adjusted Ebitda of GBP15 million, up from GBP9.8 million in 2020 but down a touch from GBP15.2 million in 2019.

----------

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Licenses RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick. "Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, which is at a late-pre-clinical development stage," company says. "The candidate, which will be developed by Poolbeg as POLB 002, was developed at the University of Warwick and derived from twenty years of research with world class virologists, Professor Andrew Easton and Professor Nigel Dimmock."

----------

Midatech Pharma PLC - Cardiff-based drug delivery technology company - Extends research and development pact with Janssen Pharmaceutical NV, owned by Johnson & Johnson. "Under the extended collaboration the company will focus on maximizing drug loading and optimizing in vitro duration of release for this undisclosed Janssen experimental molecule using the company's Q-Sphera technology," Midatech says.

----------

Helium One Global Ltd - London-based exploration & development company - Says remote sensing work at Rukwa, Eyasi and Balangida project areas finds "additional helium anomalies". "Evidence of a robust helium anomaly across the Tai structure where drilling last year encountered numerous helium shows," company says. "Multiple surface anomalies identified within all three basins that require follow up geophysical investigation."

----------

Future Metals NL - Australia-focused platinum group metals explorer - Reports "further high-grade PGM assay results" at Panton project in Australia. "Metallurgical flotation test work is underway on both high-grade and low-grade representative composite samples," Future Metals says. Notes results pending for further 52 drill holes.

----------

88 Energy Ltd - Alaska-focused oil exploration and appraisal company - Says permit to drill Merlin-2 in final stages of review by Bureau of Land Management in Alaska. Affirms project timeline. Company explains: "Permitting and planning for the Merlin-2 well is now largely complete, with the well on track to spud in February 2022. The Merlin-2 permit to drill is in the final stages of review by the BLM and is on schedule to be issued ahead of rig mobilisation."

----------

Ncondezi Energy Ltd - coal-fired power project in Mozambique - Updates on power project in Tete, Mozambique. Says awaiting further clarity on China's position on financing coal projects. Adds China Machinery Engineering Corp "remains committed" to project. Ncondezi is funded to end of first half of 2022, company adds.

----------

Drumz PLC - London-based investment company - Says 25% owned investee Acuity Risk Management Ltd wins several new customers for Stream risk management product. Says major broadcaster with "global reach" adopts Stream, ass does a "multinational German industrial control and automation company".

----------

H&T Group PLC - Surrey, England-based pawnbroker - Expects pretax profit for 2021 to be within range of current market expectations, which stand between GBP9.0 million and GBP10.1 million. "Demand for pledge lending has now fully recovered to pre-pandemic levels, with positive momentum across the customer spectrum and in all geographies. The months of November and December saw particularly strong borrowing demand, with lending volumes in December ahead of expectations and at record levels. Loan-to-value ratios have been maintained. Redemption rates remain stable and above historic norms," H&T says. "Retail sales have continued to remain robust, with consistently strong demand for high quality pre-owned watches and jewellery both online and in H&T's store network."

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
21 Dec 2022 19:20

TRADING UPDATES: Atlantis Japan underperforms; Bellevue lowers payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Dec 2022 13:37

Poolbeg identifies new drug candidates with OneThree

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.

Read more
14 Dec 2022 21:54

TRADING UPDATES: Poolbeg acquires license; Afentra expects PSA delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.